UNITY Biotechnology to Host Investor and Analyst Day to Discuss Clinical Development Program for UBX1325 in Age-Related Diseases of the Eye

Rhea-AI Summary

UNITY Biotechnology (Nasdaq: UBX) announced an Investor/Analyst Day on October 12, 2022, at 5:00 a.m. PT/8:00 a.m. ET. The event will focus on age-related eye diseases and the potential treatment solution offered by its lead program, UBX1325.

Key discussions will include insights from Robert B. Bhisitkul, M.D., Ph.D., on the mechanism of action of UBX1325, along with recent clinical data from the BEHOLD study in Diabetic Macular Edema and the ENVISION study in wet Age-related Macular Degeneration.

Positive

• Investor/Analyst Day highlights potential of UBX1325 for age-related eye diseases.
• Presentation includes new preclinical data supporting the senolytic approach.

Negative

• None.

-Webinar to feature presentation from retinal expert Robert B. Bhisitkul, M.D., Ph.D., on Wednesday, October 12 at 5:00 a.m. PT/8:00 a.m. ET-

SOUTH SAN FRANCISCO, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (Nasdaq: UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that it will host an Investor/Analyst Day on Wednesday, October 12, 2022 at 5:00 a.m. PT/8:00 a.m. ET to discuss the current treatment landscape and unmet medical need for age-related diseases of the eye, and the potential treatment solution that UNITY’s lead program, UBX1325, may provide.

Members of UNITY’s senior management team and Key Opinion Leader Robert B. Bhisitkul, M.D., Ph.D., (University of California San Francisco School of Medicine) will discuss the proposed mechanism of action of UBX1325 and new preclinical data that supports the senolytic approach in retinal diseases, the most recent UBX1325 clinical data from the BEHOLD study in Diabetic Macular Edema (DME), the ENVISION study in wet Age-related Macular Degeneration (wet AMD), including details of the new 48-week long-term follow-up extension study and near-term value driving milestones.

The live webcast can be accessed in the “Investors and Media” section of our website, www.unitybiotechnology.com, under “Events & Presentations” or by clicking here. A replay will be available two hours after the completion of the call and can be accessed in the “Investors & Media” section of our website, under “Events and Presentations.”

About UNITY
UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn.

Source: Unity Biotechnology, Inc

FAQ

What is the purpose of the Investor/Analyst Day hosted by UNITY Biotechnology on October 12, 2022?

The event aims to discuss age-related eye diseases and potential treatments, specifically focusing on UBX1325.

Who will present at the UNITY Biotechnology Investor/Analyst Day?

Robert B. Bhisitkul, M.D., Ph.D., along with UNITY's senior management team, will present.

What recent study data will be discussed for UBX1325 at the event?

Recent clinical data from the BEHOLD study in Diabetic Macular Edema and the ENVISION study in wet Age-related Macular Degeneration will be shared.

What is UBX1325 and its significance?

UBX1325 is UNITY’s lead program developing therapeutics targeting age-related eye diseases, with promising preclinical data.